These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 15573894)

  • 21. Designing clinical development programs for anti-hepatitis B virus drugs.
    Brown NA
    Methods Mol Med; 2004; 96():499-537. PubMed ID: 14762289
    [No Abstract]   [Full Text] [Related]  

  • 22. Review article: Nucleoside analogues for the treatment of chronic hepatitis B.
    Younger HM; Bathgate AJ; Hayes PC
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1211-30. PubMed ID: 15606384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
    Lo CM; Liu CL; Chan SC; Lau GK; Fan ST
    J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation.
    Trautwein C
    J Hepatol; 2004 Sep; 41(3):362-9. PubMed ID: 15336437
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of fialuridine on hepatitis B immune globulin pharmacokinetics following orthotopic liver transplant for chronic hepatitis B viral-induced cirrhosis.
    McGory RW; Ishitani MB; Oliveira WM; Stevenson WC; Dickson RC; Caldwell SH; Pruett TL
    Transplant Proc; 1995 Feb; 27(1):1213-4. PubMed ID: 7878854
    [No Abstract]   [Full Text] [Related]  

  • 26. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence.
    Wiegand J; Hasenclever D; Tillmann HL
    Antivir Ther; 2008; 13(2):211-20. PubMed ID: 18505172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of hepatitis B virus recurrence after living donor liver transplantation.
    Ali H; Egawa H; Uryuhara K; Ogawa K; Kasahara M; Ueda M; Marusawa H; Nabeshima M; Tanaka K
    Transplant Proc; 2004 Nov; 36(9):2764-7. PubMed ID: 15621143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
    Tillmann HL; Hadem J; Leifeld L; Zachou K; Canbay A; Eisenbach C; Graziadei I; Encke J; Schmidt H; Vogel W; Schneider A; Spengler U; Gerken G; Dalekos GN; Wedemeyer H; Manns MP
    J Viral Hepat; 2006 Apr; 13(4):256-63. PubMed ID: 16611192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H.
    Erhardt A; Göbel T; Ludwig A; Lau GK; Marcellin P; van Bömmel F; Heinzel-Pleines U; Adams O; Häussinger D
    J Med Virol; 2009 Oct; 81(10):1716-20. PubMed ID: 19697400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
    Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
    J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advance in clinical studies of the kinetics of hepatitis B virus].
    Tang YT; Cao Q; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):75-7. PubMed ID: 20128981
    [No Abstract]   [Full Text] [Related]  

  • 32. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation.
    Mutimer D; Pillay D; Dragon E; Tang H; Ahmed M; O'Donnell K; Shaw J; Burroughs N; Rand D; Cane P; Martin B; Buchan S; Boxall E; Barmat S; Gutekunst K; McMaster P; Elias E
    J Hepatol; 1999 Apr; 30(4):715-21. PubMed ID: 10207815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
    Kim JH; Park JW; Koh DW; Lee WJ; Kim CM
    Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options in HBV.
    Craxì A; Antonucci G; Cammà C
    J Hepatol; 2006; 44(1 Suppl):S77-83. PubMed ID: 16356581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic viral hepatitis.
    Alexander G; Walsh K
    Int J Clin Pract; 2000 Sep; 54(7):450-6. PubMed ID: 11070570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Introduction to chronic hepatitis type B].
    Inoue O; Nakagawa Y; Mawatari H
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():285-9. PubMed ID: 15453331
    [No Abstract]   [Full Text] [Related]  

  • 38. [Management of chronic hepatitis B].
    Telegdy L
    Orv Hetil; 1997 Jun; 138(22 Suppl 1):1462-5. PubMed ID: 9221375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of novel beta-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma.
    Bridges EG; Cheng YC
    Prog Liver Dis; 1995; 13():231-45. PubMed ID: 9224504
    [No Abstract]   [Full Text] [Related]  

  • 40. Update of chronic hepatitis B.
    Yuan H; Lee WM
    Curr Opin Gastroenterol; 2011 May; 27(3):217-23. PubMed ID: 21423004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.